ATNM — Actinium Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $31.06m
- -$11.06m
- $0.09m
Brief: ctinium’s Atnm-400 Shows Strong Efficacy in TNBC, Beats Therapy Resistance at SABCS
Brief: Actinium Pharmaceuticals Says ATNM-400 Shows Superior Efficacy To Xtandi In Prostate Cancer
Brief: Actinium Pharmaceuticals Announces ATNM-400 A Novel Non-PSMA Targeting First In Class Prostate Cancer Radiotherapy Leveraging Actinium-225
Brief: Actinium Pharmaceuticals Announces Supply Agreement With Eckert & Ziegler For AC-225 Radioisotope To Support Comprehensive Development Activities
Brief: Actinium begins new Actimab-A trial combining Venetoclax and ASTX-727 to treat patients newly diagnosed with AML in partnership with NCI
Brief: Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff To Its Board Of Directors
Brief: Actinium Pharmaceuticals Announces Publication Of Results From The Phase 3 Sierra Trial Of Iomab-B
U.S. RESEARCH ROUNDUP- Actinium Pharmaceuticals, Albemarle, ArcBest
Brief: Actinium Provides Regulatory Update On Planned BLA Filing And Future Plans For Iomab-B In The U.S.
Brief: Actinium Gets FDA Clearance of Iomab-ACT Targeted Conditioning IND Application
Advisory: Alert from FN Media Group wrongly tagged to multiple companies withdrawn
Brief: Actinium Highlights Oral Presentation At Eha 2024 Annual Congress
Brief: Actinium Highlights Mutation Data From The Phase 3 Sierra Trial Of Iomab-B And Novel Linker Technology To Support Solid Tumor Antibody Radiation Conjugate Development At The 2024 Society Of Nuclear Medicine & Molecular Imaging Annual Meeting
Brief: Actinium Announces KOL Webinar to Highlight Recently Announced Iomab-ACT Trial with Leading FDA Approved Commercial CAR T-Cell Therapy Being Led by the University of Texas Southwestern
Brief: Actinium Announces Clinical Trial to Study Targeted Radiotherapy Conditioning with FDA Approved CAR T-Cell Therapy
Live Markets: Big pharma's FOMO will lead to more radio M&A
Brief: Actinium Pharmaceuticals Reports New Analyses From Positive Phase 3 Trial of Iomab-B
Brief: Actinium Pharmaceuticals Highlights Improved Survival With Iomab-B In TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients In SIERRA Trial
Brief: Actinium Announces Iomab-B Produces High Response Rates and Significant Improvement in Overall Survival in Relapsed Refractory AML Patients with Active Disease Overcoming TP53 Mutation